Stockreport

Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10

Aptevo Therapeutics Inc.  (APVO) 
Last aptevo therapeutics inc. earnings: 8/9 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aptevotherapeutics.com/investor-overview
PDF Suppresses Inflammation and Immune Activation Without Lymphocyte Stimulation New Preclinical Data Published in ‘Frontiers in Immunology’ Show APVO210 Holds Promise in t [Read more]